Browsing: BioCryst

CNBC Cures is proudly under AstraZeneca Rare Disease, whose support enables our journalism to elevate stories that advance research, innovation and patient care in rare diseases

Capitalize on the AI infrastructure supercycle with our selection of the 54 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow

BioCryst Pharmaceuticals has appointed David W. Jenkins, Ph.D., as its first chief scientific officer, a newly created executive role designed to strengthen the company’s research strategy as it expands its rare disease pipeline through external innovation and partnerships. The appointment is effective immediately, with Jenkins reporting to Chief Research and Development Officer Dr. Sandeep Menon…

To own BioCryst today, you need to believe that ORLADEYO and a focused rare disease franchise can support the business while externallydiscovery does not change the near term focus on ORLADEYO execution and key data and regulatory milestones, but it does increase uncertainty around long term research productivity and the company’s ability to replace its…